ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1652907
This article is part of the Research TopicAdvancing Livestock Health: Innovative Vaccine Strategies to Combat Antimicrobial ResistanceView all articles
Evaluation of a Multi-Epitope Vaccine PME for Pasteurella multocida in Mouse Model
Provisionally accepted
- 1Yangtze University, Jingzhou, China
- 2Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pasteurella multocida (P. multocida) is the pathogen responsible for swine pasteurellosis, which can impede their growth and even cause death, leading huge economic losses to the global pig industry. P. multocida can be divided into 5 serotypes, and existing vaccines have low cross-immunity protection. Therefore, developing a vaccine that can provide effective cross-protection is essential for preventing swine pasteurellosis and reducing the abuse of antibiotics. In this study, six dominant antigenic proteins of P. multocida (PlpE, OmpA, OmpH, VacJ, Omp87 and Cp39) were selected. Through bioinformatics methods, 20 B-cell epitopes, 7 CTL epitopes and 11 Th-cell epitopes were predicted. The multi-epitope antigen PME was constructed by connecting these epitopes with linkers, and then the recombinant protein His-PME and the recombinant plasmid pcDNA3.1-PME could effectively stimulate immunized mice to produce antibodies, IL-4 and IFN-γ. The protection rates of His-PME group and pcDNA3.1-PME group were 62.5% and 75% against P. multocida serotype A, and 87.5% and 100% against P. multocida serotype D, respectively. Furthermore, the pathological lung damages in the His-PME group and the pcDNA3.1 PME group were significantly alleviated, and the bacterial loads in lung tissues were significantly decreased. These results indicated that the subunit vaccine His-PME and the DNA vaccine pcDNA3.1 PME can effectively resist the infection of P. multocida and have good immunogenicity and cross-protection. Therefore, the multi-epitope vaccine PME can be regarded as a candidate vaccine for the prevention of P. multocida infection.
Keywords: B-cell, B lymphocyte, CTL, cytotoxic T lymphocyte, IEDB, Immune Epitope Database and Tools, IFN-γ, interferon gamma, IL-4, interleukin-4, IPTG, isopropyl β-D-1-thiogalactopyranoside, MHC I, major histocompatibility PlpE, outer membrane lipoprotein, VacJ, VacJ family lipoprotein
Received: 24 Jun 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Zhang, 戴, Jia, Qi, He, Chen, Gao, Lei and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Feng Liu, Yangtze University, Jingzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.